Summary
This study investigated regular treatment with the long-acting β2-agonist formoterol over 5 years in patients with predominantly moderate to severe bronchial asthma. It was an open, prospective, surveillance study in 54 randomly selected asthmatics that considered concomitant medication, pulmonary function, exacerbations and the patients’ subjective condition. The objective findings were compared with the corresponding data for the previous 12 months. Five follow-up examinations were carried out for 5 consecutive years. The mean number of 12µg puffs of formoterol inhaled per day over 5 years was 2.5, 2.5, 2.6, 2.5 and 2.2, for each consecutive year. The number of patients who used an electric nebuliser fell from 41 (pretrial period) to 6, 4, 3, 1 and 1, consecutively over the 5-year period (p < 0.001). The total number of patients using theophylline fell from 31 to 9 in the first year, and dropped to 4 at the end of the trial (p < 0.001). The percentage of patients on inhaled corticosteroids remained more or less constant (72 vs 75%). The mean daily use of beclomethasone dipropionate decreased from 2.8 to 1.9 puffs daily after 1 year and remained at this level (p < 0.05). During the pretrial period, 27 patients had exacerbations necessitating treatment with systemic corticosteroids. This number fell to 12, 5, 11, 6 and 9 over the consecutive years, and the mean number of interventions decreased from 1.6 to 0.2 at the end of the trial (p < 0.001). Over 5 years of treatment, the mean decrease in forced expiratory volume in the first second (FEV1) was 0.11 ±0.52L and the mean reversibility fell by 0.001 ± 0.36L, indicating a high stability of lung function. Adverse effects occurred in 19 of 66 patients (29%). Two patients died. Neither of the deaths was judged to be related to the therapy with formoterol. In conclusion, regular therapy with formoterol appears to be very useful; there was a significant reduction in concomitant use of asthma drugs, with well-preserved pulmonary function, better subjective condition and less need for corticosteroid intervention treatment. No increase in the formoterol dose was observed, indicating no clinically relevant development of tolerance. Furthermore, no patient had to be withdrawn because of adverse effects.
Similar content being viewed by others
References
Sears MR, Taylor DR, Print CG, et al. Regular inhaled β-agonist treatment in bronchial asthma. Lancet 1990; 336: 1391–6
Van Schayck CP, Dompeling E, van Herwaarden CLA, et al. Bronchodilator treatment in moderate asthma or chronic bronchitis: continuous or on demand? A randomised controlled study. BMJ 1991; 303: 1426–31
Vathenen AS, Knox AJ, Higgins BG, et al. Rebound increase in bronchial responsiveness after treatment with inhaled terbutaline. Lancet 1988; 1: 554–8
Tasake K. Formoterol (Atock): a new orally active and selective β2-receptor stimulant. Drugs Today 1986; 22: 505–19
Arvidsson P, Larsson S, Löfdahl CG, et al. Formoterol, a new long-acting bronchodilator for inhalation. Eur Respir J 1989; 2: 325–30
Kesten S, Chapman KR, Broder I, et al. Sustained improvement in asthma with long term use of formoterol fumarate. Ann Allergy 1992; 69: 415–6
Wallin A, Melander B, Rosenhall L, et al. Formoterol, a new long-acting β2-agonist for inhalation twice daily compared with salbutamol in the treatment of asthma. Thorax 1990; 45: 259–61
Arvidsson P, Larsson S, Löfdahl CG, et al. Inhaled formoterol during one year in asthma: a comparison with salbutamol. Eur Respir J 1991; 4: 1168–73
Schultze-Werninghaus G. Multicenter 1-year trial on formoterol, a new long-acting β2-agonist, in chronic obstructive airway disease. Lung 1990; 168 Suppl.: 83–9
American Thoracic Society. Definitions and classification of chronic bronchitis, asthma and pulmonary emphysema. Am Rev Respir Dis 1962; 82: 762–8
National Asthma Education Program. Executive summary: guidelines for the diagnosis and management of asthma. National Heart, Lung and Blood Institute, NIH, Bethesda, Maryland, USA. Publication No. 91-3042 A, June 1991
American Thoracic Society. Standardisation of spirometry, 1987 update. Am Rev Respir Dis 1987; 130: 1296–2009
Lienert GA. Verteilungsfreie Methoden in der Biostatistik. Vol. 1. Meisenheim am Glan: Anton Hain, 1986
Van Schayck CP, Dompeling E, van Hexwaarden CL, et al. Continuous and on demand use of bronchodilators in patients with non-steroid dependent asthma and chronic bronchitis: four-year follow-up randomised controlled study. Br J Gen Pract 1995; 45: 239–44
Barnes N. Efficacy and effectiveness in the treatment of patients with asthma. Eur Respir Rev 1995; 5: 284–7
Moertel CG. Improving the efficiency of clinical trials, a medical perspective. Stat Med 1984; 3: 455–65
Pocock SJ. Letter to the editor. BMJ 1977; 1: 1661
Gehan EA. The evaluation of therapies: historical control studies. Stat Med 1984; 3: 315–24
Lasagna L. Historical control: the practitioner’s clinical trials. N Engl J Med 1982; 307: 1339–40
Idris A, McDermott MF, Raucci JC, et al. Emergency department treatment of severe asthma. Metered-dose inhaler plus holding chamber is equivalent in effectiveness to nebulizer. Chest 1993; 103: 665–72
Fletcher C, Peto R, Tinker C, et al. The natural history of chronic bronchitis and emphysema. Oxford: Oxford University Press, 1976
Dompeling E, van Schayck CP, van Grunsven PM, et al. Slowing the deterioriation of asthma and chronic obstructive pulmonary disease observed during bronchodilator therapy by adding inhaled corticosteroids: a 4-year prospective study. Ann Intern Med 1993; 118: 770–8
Britton MG, Earnshaw JS, Palmer JBD. A 12-month comparison of salmeterol with salbutamol in asthmatic patients. Eur Respir J 1992; 5: 1062–7
D’Alonzo GE, Nathan RA, Henochowicz S, et al. Twice daily inhaled salmeterol as maintenance therapy for asthma. JAMA 1994; 271: 1412–5
Lundbäck R, Rawlinson DW, Palmer JBD. A 12-month comparison of salbutamol as dry powder formulations in asthmatic patients. Thorax 1993; 48: 148–53
Pearlman DS, Chervinsky P, La Force G, et al. A comparison of salbutamol with salmeterol in the treatment of mild to moderate asthma. N Engl J Med 1992; 327: 1420–5
Tattersfield AE. Tolerance to beta-agonists. Bull Eur Physiopathol Respir 1985; 21: 1s–5s
Newnham DM, Grove A, McDevitt DG, et al. Subsensitivity of bronchodilatator and systemic beta-2-adrenoceptor responses after regular twice daily treatment with formoterol dry powder in asthmatic patients. Thorax 1995; 50: 497–504
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Häcki, M.A., Hinz, G.W. & Medici, T.C. Clinical Experience over Five Years of Daily Therapy with Formoterol in Patients with Bronchial Asthma. Clin. Drug Invest. 14, 165–174 (1997). https://doi.org/10.2165/00044011-199714030-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00044011-199714030-00002